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Chronic obstructive pulmonary disease (COPD) is currently defined by
persistent airflow limitation with enhanced and chronic airways inflamma-
tion [1]. Nevertheless, the clinical management of the disease is based on
measuring symptoms, airflow limitation and exacerbation frequency [1]. Do
we need to assess airways inflammation to optimize the management of
COPD? When using factor analysis it appears that inflammation and airflow
limitation represent partly independent features of the disease [2,3].
COPD is a heterogeneous disorder with widespread variability in airway and
parenchymal histology [4]. It is close to impossible to sample this histology
adequately, which has hampered progress in COPD research. The current
‘silver standard’ is represented by endobronchial biopsies of the large
airways and bronchoalveolar lavage, which provide different and selective
samples of airway inflammation [5,6]. These quantitative measurements can
be used in clinical research, in which the efficacy of anti-inflammatory
intervention in COPD is validated by showing e.g. reduction of inflammation
at the airway level [7].
However, these methods are unsuitable for monitoring inflammation in COPD.
Which less invasive methods are available for this? This may include peripheral
blood [8], but certainly refers to (induced) sputum analysis. It has nicely been
shown that guiding regular anti-inflammatory therapy in COPD by monitoring
eosinophilic inflammation in sputum leads to a dramatic reduction in
exacerbations [9]. This exceeds the effects of most novel drugs, and thereby
points the way towards phenotype-driven, personalized medicine in COPD.
Nevertheless, even sputum analysis is laborious. Therefore, recent attempts
have focused on capturing molecular signatures of exhaled air in COPD by
using electronic noses. It appears that such ‘breathprints’ can be typical for
COPD [10,11] and that the molecular constituents in exhaled air are
associated with the eosinophilic and neutrophilic subtypes in COPD [12].
This is encouraging, because it may allow real-time monitoring of inflam-
matory phenotypes and thereby the tailoring of individual therapy in COPD.
In conclusion, at present inflammation has only a very limited role, if any, in
the diagnosis and therapy of COPD. However, there is strong evidence that
monitoring inflammation contributes to a better disease outcome, which
may become feasible with doctor’s office technology.
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Lung cancer screening trials provide an opportunity to study the natural
history of emphysema by using CT lung density as a surrogate parameter.
In the Danish Lung Cancer Screening Trial, 4,104 participants were
randomized to either annual screening with low dose CT for 5 years
(2005-2009) or no screening (control group). Participants were 50-70 years
of age, current or ex-smoker with minimum 20 pack-years, and FEV1 of at
least 30% of predicted normal at baseline. Ex-smokers had to have quit af-
ter the age of 50 years and less than 10 years before inclusion. In addition,
measurements from individuals who changed their smoking habit during
the study, where excluded from the current analysis from the date of
change of smoking habit. At screening rounds, smoking habits were
recorded and spirometry was performed. CT lung density was measured
as the volume-adjusted 15th percentile density (PD15). Almost half (47%)
had airflow obstruction (AFO) at study entry. The influences of age, sex,
height, BMI, smoking and AFO on FEV1 and PD15 were analyzed in mixed
effects multiple regression models. A progressive decline in FEV1 has
been widely accepted as the hallmark of COPD. However, recent evidence
indicates that the rate of FEV1 decline is higher in mild to moderate COPD
than in severe COPD. Usually changes in FEV1 are measured in ml that is
absolute, however, changes can also be measured relative as a percentage
of the actual FEV1. In absolute terms those with the best FEV1 consistently
showed the steepest decline, whereas in relative terms most fast decliners
were found among those with low FEV1, which seems more intuitive.
Furthermore, relative measurements implied statistically significant accel-
eration of decline with advancing age, smoking (pack-years) and severity
of AFO. Female sex and current smoking increased PD15 at baseline, and
both increased the annual decline in PD15. The presence and severity of
AFO was a strong predictor of low PD15 at baseline and of increased annual
decline in PD15. In conclusion, relative measurements lead to a better un-
derstanding of changes in FEV1, and PD15 as a measure of structural
changes in COPD seems to be are more sensitive indicator of progression
of disease.
